Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

In Type 2 diabetes, Junevity’s first siRNA therapeutic candidate improved glucose control and insulin sensitivity in diabetic mice without causing weight gain or other side effects associated ...

highlighted by its blockbuster diabetes drug Mounjaro (tirzepatide) which pulled in $5.2bn global sales in 2023, as per Lilly's financials. GalNAc is a widely used delivery method for siRNA ...

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

Junevity Inc. has raised $10 million in seed funding to support its work creating silencing RNA (siRNA) therapeutics to address metabolic and age-related diseases, including type 2 diabetes, obesity ...

In this study, the authors demonstrated that exosomes can serve as delivery vehicles to introduce AGO2-loaded siRNA into the cytoplasm of bacteria, and in turn down-regulated gene expression of ...

Diabetes is a chronic disease that occurs when ... To this end, small interfering ribonucleic acid (siRNA) knockdown of 16 GPCRs was performed, followed by protein quantification and ...